Trial Outcomes & Findings for Open-label Drug Interaction Study Between Eslicarbazepine Acetate and Phenytoin. (NCT NCT02283827)
NCT ID: NCT02283827
Last Updated: 2014-12-18
Results Overview
BIA 2-194 and BIA 2-195 are metabolites of eslicarbazepine acetate
Recruitment status
COMPLETED
Study phase
PHASE1
Target enrollment
32 participants
Primary outcome timeframe
Day 8 and 27: within 5 minutes prior to dosing and 0.5,1,1.5,2,2.5,3,3.5,4,6,9,12,16 and 24 hours after drug administration
Results posted on
2014-12-18
Participant Flow
Participant milestones
| Measure |
Group A BIA 2-093 + Phenytoin (PHT)
Day 1 to 2: Pre-treatment 1: ESL 600 mg Day 3 to 8: Treatment 1:1200 mg ESL Day 9 to 10: Treatment 1 + Pre-treatment 2: 1200 mg ESL+ PHT 100 mg Day 11 to 27: Treatment 1 + Treatment 2: 1200 mg ESL + PHT 300 mg
|
Group B BIA 2-093 + Phenytoin (PHT)
Day 1 to 2: Pre-treatment 2: PHT 100 mg Day 3 to 8: Treatment 2: PHT 300 mg Day 9 to 10: Treatment 2 + Pre-treatment 1: PHT 300 mg
\+ ESL 600 mg Day 11 to 27: Treatment 1 + Treatment 2: 1200 mg ESL + PHT 300 mg
|
|---|---|---|
|
Overall Study
STARTED
|
16
|
16
|
|
Overall Study
COMPLETED
|
15
|
13
|
|
Overall Study
NOT COMPLETED
|
1
|
3
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Open-label Drug Interaction Study Between Eslicarbazepine Acetate and Phenytoin.
Baseline characteristics by cohort
| Measure |
Group A BIA 2-093 + Phenytoin (PHT)
n=16 Participants
Pre-treatment: 600 mg ESL, 2 days; Treatment 1: 1200 mg ESL 6 days Treatment 2: 1200 mg ESL and PHT 100 mg for 2 days Treatment 3: 1200 mg ESL and PHT 300 mg for17 days
|
Group B BIA 2-093 + Phenytoin (PHT)
n=16 Participants
Pre-treatment: 100 mg PHT for 2 days; Treatment 1: 300 mg PHT 6 days; Treatment 2: 600 mg ESL + PHT 300 mg for 2 days; Treatment 3: 1200 mg ESL and PHT 300 mg for 17 days
|
Total
n=32 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Categorical
<=18 years
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
|
Age, Categorical
Between 18 and 65 years
|
16 Participants
n=5 Participants
|
16 Participants
n=7 Participants
|
32 Participants
n=5 Participants
|
|
Age, Categorical
>=65 years
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
|
Sex: Female, Male
Female
|
0 Participants
n=5 Participants
|
0 Participants
n=7 Participants
|
0 Participants
n=5 Participants
|
|
Sex: Female, Male
Male
|
16 Participants
n=5 Participants
|
16 Participants
n=7 Participants
|
32 Participants
n=5 Participants
|
PRIMARY outcome
Timeframe: Day 8 and 27: within 5 minutes prior to dosing and 0.5,1,1.5,2,2.5,3,3.5,4,6,9,12,16 and 24 hours after drug administrationBIA 2-194 and BIA 2-195 are metabolites of eslicarbazepine acetate
Outcome measures
| Measure |
BIA 2-093 + Phenytoin
n=28 Participants
Phenytoin - PHT; BIA 2-093 - ESL, Eslicarbazepine
|
BIA 2-093
n=15 Participants
BIA 2-093 - ESL, Eslicarbazepine
|
|---|---|---|
|
Cmax - the Maximum Plasma Concentration
Cmax (PHT)
|
12868.5 ng/mL
Standard Deviation 6292.7
|
9405.1 ng/mL
Standard Deviation 3621
|
|
Cmax - the Maximum Plasma Concentration
Cmax (BIA 2-194)
|
16350.6 ng/mL
Standard Deviation 2060.2
|
23806.5 ng/mL
Standard Deviation 3047.2
|
|
Cmax - the Maximum Plasma Concentration
Cmax (BIA 2-195)
|
976.9 ng/mL
Standard Deviation 194.4
|
954.3 ng/mL
Standard Deviation 189.9
|
SECONDARY outcome
Timeframe: Day 8 and 27: within 5 minutes prior to dosing and 0.5,1,1.5,2,2.5,3,3.5,4,6,9,12,16 and 24 hours after drug administrationAUC0-t - the Area Under the Plasma Concentration-time Curve From Time Zero to the Last Sampling Time BIA 2-194 and BIA 2-195 are metabolites of eslicarbazepine acetate
Outcome measures
| Measure |
BIA 2-093 + Phenytoin
n=28 Participants
Phenytoin - PHT; BIA 2-093 - ESL, Eslicarbazepine
|
BIA 2-093
n=15 Participants
BIA 2-093 - ESL, Eslicarbazepine
|
|---|---|---|
|
AUC0-t - the Area Under the Plasma Concentration-time Curve From Time Zero to the Last Sampling Time
AUC0-t (BIA 2-194)
|
251055.2 ng*h/mL
Standard Deviation 34143.1
|
371574.9 ng*h/mL
Standard Deviation 43474.3
|
|
AUC0-t - the Area Under the Plasma Concentration-time Curve From Time Zero to the Last Sampling Time
AUC0-t (BIA 2-195)
|
19471.2 ng*h/mL
Standard Deviation 4069.5
|
20675.0 ng*h/mL
Standard Deviation 4362.4
|
|
AUC0-t - the Area Under the Plasma Concentration-time Curve From Time Zero to the Last Sampling Time
AUC0-t (PHT)
|
264784.8 ng*h/mL
Standard Deviation 137688.1
|
186826.5 ng*h/mL
Standard Deviation 81643.2
|
SECONDARY outcome
Timeframe: Day 8 and 27: within 5 minutes prior to dosing and 0.5,1,1.5,2,2.5,3,3.5,4,6,9,12,16 and 24 hours after drug administrationBIA 2-194 and BIA 2-195 are metabolites of eslicarbazepine acetate
Outcome measures
| Measure |
BIA 2-093 + Phenytoin
n=28 Participants
Phenytoin - PHT; BIA 2-093 - ESL, Eslicarbazepine
|
BIA 2-093
n=15 Participants
BIA 2-093 - ESL, Eslicarbazepine
|
|---|---|---|
|
Tmax - the Time of Occurrence of Cmax
Tmax (BIA 2-194)
|
3.00 hours
Standard Deviation 1.02
|
2.50 hours
Standard Deviation 0.95
|
|
Tmax - the Time of Occurrence of Cmax
Tmax (BIA 2-195)
|
9.00 hours
Standard Deviation 1.49
|
9.00 hours
Standard Deviation 4.03
|
|
Tmax - the Time of Occurrence of Cmax
Tmax (PHT)
|
4.00 hours
Standard Deviation 1.96
|
4.00 hours
Standard Deviation 2.35
|
Adverse Events
BIA 2-093 600 mg
Serious events: 0 serious events
Other events: 3 other events
Deaths: 0 deaths
BIA 2-093 1200 mg
Serious events: 0 serious events
Other events: 12 other events
Deaths: 0 deaths
BIA 2-093 1200 mg + Phenytoin 100 mg
Serious events: 0 serious events
Other events: 7 other events
Deaths: 0 deaths
BIA 2-093 1200 mg + Phenytoin 300 mg
Serious events: 0 serious events
Other events: 27 other events
Deaths: 0 deaths
Phenytoin 100 mg
Serious events: 0 serious events
Other events: 7 other events
Deaths: 0 deaths
Phenytoin 300 mg
Serious events: 0 serious events
Other events: 10 other events
Deaths: 0 deaths
BIA 2-093 600 mg + Phenytoin 300 mg
Serious events: 0 serious events
Other events: 8 other events
Deaths: 0 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
| Measure |
BIA 2-093 600 mg
n=16 participants at risk
BIA 2-093 - ESL, Eslicarbazepine
|
BIA 2-093 1200 mg
n=16 participants at risk
BIA 2-093 - ESL, Eslicarbazepine
|
BIA 2-093 1200 mg + Phenytoin 100 mg
n=16 participants at risk
Phenytoin - PHT BIA 2-093 - ESL, Eslicarbazepine
|
BIA 2-093 1200 mg + Phenytoin 300 mg
n=32 participants at risk
Phenytoin - PHT BIA 2-093 - ESL, Eslicarbazepine
|
Phenytoin 100 mg
n=16 participants at risk
Phenytoin - PHT 100 mg
|
Phenytoin 300 mg
n=16 participants at risk
Phenytoin - PHT 300 mg
|
BIA 2-093 600 mg + Phenytoin 300 mg
n=16 participants at risk
Phenytoin - PHT BIA 2-093 - ESL, Eslicarbazepine
|
|---|---|---|---|---|---|---|---|
|
Gastrointestinal disorders
Abdominal distension
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
6.2%
2/32 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
|
Ear and labyrinth disorders
Ear pain
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
3.1%
1/32 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
|
Gastrointestinal disorders
Diarrheoa
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
6.2%
1/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/32 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
|
Gastrointestinal disorders
Dyspepsia
|
6.2%
1/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
9.4%
3/32 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
|
Gastrointestinal disorders
Oral pain
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
6.2%
2/32 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
|
Gastrointestinal disorders
Toothache
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
3.1%
1/32 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
6.2%
1/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
|
General disorders
Fatigue
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
18.8%
3/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
6.2%
1/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
9.4%
3/32 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
6.2%
1/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
6.2%
1/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
|
General disorders
Feeling drunk
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
6.2%
1/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
6.2%
2/32 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
|
General disorders
Feeling hot
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
6.2%
1/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
3.1%
1/32 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
|
General disorders
Hot flush
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
6.2%
1/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/32 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
|
General disorders
Local swelling
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
6.2%
2/32 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
|
Injury, poisoning and procedural complications
Injury
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
6.2%
2/32 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
|
Investigations
Body temperature increased
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
6.2%
1/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/32 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
|
Metabolism and nutrition disorders
Decreased appetite
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
3.1%
1/32 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
|
Metabolism and nutrition disorders
Increased appetite
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
3.1%
1/32 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
|
Musculoskeletal and connective tissue disorders
Bone swelling
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
3.1%
1/32 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
|
Musculoskeletal and connective tissue disorders
Muscle spasms
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
9.4%
3/32 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
6.2%
1/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal stiffness
|
6.2%
1/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/32 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
|
Musculoskeletal and connective tissue disorders
Myalgia
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
6.2%
1/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/32 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
|
Nervous system disorders
Disturbance in attention
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
9.4%
3/32 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
18.8%
3/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
12.5%
2/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
|
Nervous system disorders
Dizziness
|
6.2%
1/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
6.2%
1/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
6.2%
1/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
31.2%
10/32 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
6.2%
1/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
6.2%
1/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
|
Nervous system disorders
Headache
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
18.8%
3/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
12.5%
2/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
25.0%
8/32 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
6.2%
1/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
6.2%
1/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
|
Nervous system disorders
Insomnia
|
12.5%
2/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
6.2%
1/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
3.1%
1/32 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
|
Nervous system disorders
Paraesthesia oral
|
6.2%
1/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
18.8%
3/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
12.5%
4/32 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
|
Nervous system disorders
Somnolence
|
6.2%
1/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
43.8%
7/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
25.0%
4/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
34.4%
11/32 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
37.5%
6/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
6.2%
1/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
18.8%
3/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
|
Nervous system disorders
Tremor
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
6.2%
1/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
3.1%
1/32 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
|
Nervous system disorders
Vision blurred
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
3.1%
1/32 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
|
Psychiatric disorders
Anxiety
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
6.2%
1/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
3.1%
1/32 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
|
Psychiatric disorders
Erection increased
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
6.2%
1/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/32 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
|
Respiratory, thoracic and mediastinal disorders
cough
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
12.5%
2/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
3.1%
1/32 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
6.2%
1/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
|
Respiratory, thoracic and mediastinal disorders
Nasal congestion
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
6.2%
1/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
6.2%
2/32 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
|
Respiratory, thoracic and mediastinal disorders
Pharyngolaryngeal pain
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
18.8%
3/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
6.2%
1/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/32 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
6.2%
1/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
|
Respiratory, thoracic and mediastinal disorders
Rhinorrhoea
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
6.2%
1/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
6.2%
1/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/32 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
6.2%
1/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
6.2%
1/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
|
Skin and subcutaneous tissue disorders
Alopecia
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
3.1%
1/32 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
|
Skin and subcutaneous tissue disorders
Erythema
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
9.4%
3/32 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
|
Skin and subcutaneous tissue disorders
Hair disorder
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
3.1%
1/32 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
|
Skin and subcutaneous tissue disorders
Pruritus
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
6.2%
2/32 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
|
Skin and subcutaneous tissue disorders
Rash
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
15.6%
5/32 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
6.2%
1/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
|
Cardiac disorders
Palpitations
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/32 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
6.2%
1/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
|
Eye disorders
Diplopia
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
6.2%
2/32 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
|
Eye disorders
Pupils unequal
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
3.1%
1/32 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
|
Gastrointestinal disorders
Abdominal discomfort
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/32 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
6.2%
1/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
|
Gastrointestinal disorders
Constipation
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
3.1%
1/32 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
|
Gastrointestinal disorders
Abdominal pain
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
3.1%
1/32 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
|
Gastrointestinal disorders
Dry mouth
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
3.1%
1/32 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
|
Gastrointestinal disorders
Dry throat
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
3.1%
1/32 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
|
Gastrointestinal disorders
Dysguesia
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
3.1%
1/32 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
|
Gastrointestinal disorders
Lip dry
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/32 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
6.2%
1/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
|
Gastrointestinal disorders
Nausea
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
6.2%
2/32 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
|
Gastrointestinal disorders
Tooth abscess
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
3.1%
1/32 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
|
Gastrointestinal disorders
Vomiting
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
3.1%
1/32 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
|
General disorders
Feeling cold
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/32 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
6.2%
1/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
|
General disorders
Vessel puncture site reaction
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
3.1%
1/32 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
|
Immune system disorders
Hypersensitivity
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
3.1%
1/32 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
|
Immune system disorders
Hypersensitivity syndrome
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
3.1%
1/32 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
|
Investigations
Blood chloride decreased
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
6.2%
2/32 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
|
Investigations
Blood sodium decreased
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
6.2%
2/32 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
|
Investigations
white blood cell count increased
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
3.1%
1/32 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
3.1%
1/32 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
6.2%
1/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
6.2%
1/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
|
Musculoskeletal and connective tissue disorders
Joint swelling
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/32 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
6.2%
1/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
|
Musculoskeletal and connective tissue disorders
Muscular weakness
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/32 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
6.2%
1/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
|
Musculoskeletal and connective tissue disorders
Pain
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/32 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
|
Musculoskeletal and connective tissue disorders
Sensation of heaviness
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/32 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
6.2%
1/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
|
Nervous system disorders
Paraesthesia
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
3.1%
1/32 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
|
Nervous system disorders
Sensory disturbance
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
3.1%
1/32 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
6.2%
1/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
|
Psychiatric disorders
Euphoric mood
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/32 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
6.2%
1/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
|
Psychiatric disorders
Irritability
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
3.1%
1/32 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
|
Renal and urinary disorders
Nocturia
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
3.1%
1/32 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
|
Respiratory, thoracic and mediastinal disorders
Aphonia
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/32 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
6.2%
1/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
|
Respiratory, thoracic and mediastinal disorders
Sinus congestion
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/32 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
6.2%
1/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
|
Respiratory, thoracic and mediastinal disorders
Throat irritation
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
3.1%
1/32 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
|
Skin and subcutaneous tissue disorders
Rash generalised
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
3.1%
1/32 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
|
Musculoskeletal and connective tissue disorders
Pain in extremity
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/32 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
6.2%
1/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
0.00%
0/16 • Day 8 was used for BIA 2-093 group and Day 27 was used for BIA 2-093 + Phenytoin group
|
Additional Information
Head of Clinical Research
Bial - Portela & Cª, S.A.
Phone: +351 229 866 100
Email: [email protected]
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place
Restriction type: OTHER